ProtoKinetix, Incorporated (PKTX)
| Market Cap | 2.87M -17.8% |
| Revenue (ttm) | n/a |
| Net Income | -376.17K |
| EPS | -0.00 |
| Shares Out | 409.53M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 150,000 |
| Average Volume | 157,110 |
| Open | 0.0060 |
| Previous Close | 0.0069 |
| Day's Range | 0.0060 - 0.0060 |
| 52-Week Range | 0.0040 - 0.0124 |
| Beta | 0.66 |
| RSI | 53.37 |
| Earnings Date | Apr 2, 2026 |
About ProtoKinetix
ProtoKinetix, Incorporated, a research and development stage bio-technology company, focuses on the scientific medical research of anti-freeze glycoproteins (AFGPs) or anti-aging glycoproteins (AAGPs). Its AFGPs are used in various commercial applications comprising targeted health care solutions, as well as AAGPs are used for applications in ophthalmology, dermatology, transplants, and biomanufacturing areas. The company was formerly known as RJV Network, Inc. and changed its name to ProtoKinetix, Incorporated in July 2003. ProtoKinetix, Incor... [Read more]
Financial Performance
Financial StatementsNews
Research Paper Incorporating ProtoKinetix AAGP® Submitted to Scientific Journal for Publication
DALTON, Ohio--(BUSINESS WIRE)---- $PKTX #AMD--Research Paper Incorporating ProtoKinetix AAGP® Submitted to Scientific Journal for Publication.
ProtoKinetix Successfully Completes Phase 1 Clinical Trials for the Treatment of Type 1 Diabetes in Islet Cell Transplants
MARIETTA, Ohio--(BUSINESS WIRE)---- $PKTX #AMD--ProtoKinetix Successfully Completes Phase 1 Clinical Trials for the Treatment of Type 1 Diabetes in Islet Cell Transplants
ProtoKinetix Announces Annual General Stockholder Meeting Will Be Held Virtually Only
MARIETTA, Ohio--(BUSINESS WIRE)--ProtoKinetix Announces Annual General Stockholder Meeting Will Be Held Virtually Only
Equinor and bp Achieve Key Step in Advancing Offshore Wind for New York
NEW YORK--(BUSINESS WIRE)--Today, at an event with U.S. Secretary of Energy Jennifer Granholm, New York Governor Kathy Hochul, and U.S. Representative Paul Tonko, Equinor and bp announced the finaliza...
ProtoKinetix Announces Selection of AAGP® Candidate Formulations for Treatment of Dry Eye Disease
MARIETTA, Ohio--(BUSINESS WIRE)--ProtoKinetix Announces Selection of AAGP® Candidate Formulations for Treatment of Dry Eye Disease
ProtoKinetix and IQVIA Partner to Support Development of AAGP® Product in the Treatment of Ocular Conditions
MARIETTA, Ohio--(BUSINESS WIRE)---- $PKTX #AMD--ProtoKinetix and IQVIA Partner to Support Development of AAGP® Product in the Treatment of Ocular Conditions